Dr. Tanja Obradovic brings more than 25 years of experience in pharmaceutical development in oncology. As strategy lead, she led immunotherapy development and life cycle management across tumor types, including melanoma, lung, women’s cancers, and other indications. Her work includes clinical development, medical affairs strategy, and research collaborations for over 30 novel drug entities across tumor indications. In her work, Dr. Obradovic also serves as a leader of medical collaborations and a member of Corporate Councils for early and late immuno-oncology assets with several consortia.